Efficacy, Safety, and Quality of Life With Futibatinib in Patients With Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements: Interim Analysis of FOENIX-CCA2
Lipika Goyal,1 Junji Furuse,2 Funda Meric-Bernstam,3 Antoine Hollebecque,4 Juan W. Valle,5,6 Chigusa Morizane,7 Thomas B. Karasic,8 Thomas A. Abrams,9 Robin Kate Kelley,10 Philippe A. Cassier,11 Heinz-Josef Klümpen,12 Nataliya V. Uboha,13 Amit Mahipal,14 Edith Mitchell,15 Eugene Ahn,16 Heung-Moon Chang,17 Kunihiro Masuda,18 Yaohua He,19 Karim A. Benhadji,19 John A. Bridgewater20
1Massachusetts General Hospital, Boston, MA, USA; 2Kyorin University, Faculty of Medicine, Tokyo, Japan; 3University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4Drug Development, Institut Gustave Roussy, Villejuif, France; 5University of Manchester, Manchester, UK; 6The Christie NHS Foundation Trust, Manchester, UK; 7National Cancer Center Hospital, Tokyo, Japan; 8Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 9Dana-Farber Cancer Institute, Boston, MA, USA; 10University of California, San Francisco, CA, USA; 11Centre Léon-Bérard, Lyon, FR; 12Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; 13University of Wisconsin, Carbone Comprehensive Cancer Center, Madison, WI, USA; 14Mayo Clinic, Rochester, MN, USA; 15Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA, USA; 16Cancer Treatment Centers of America Chicago, Zion, IL, USA; 17Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; 18Tohoku University Graduate School of Medicine, Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan; 19Taiho Oncology, Inc., Princeton, NJ, USA; 20UCL Cancer Institute, London, UK